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INTRODUCTION
Since the early 1980s an intensive clinical research on larynx pr-
eservation has been exploring potential reliable alternatives to
mutilating surgery defined as the complete removal of the voice
box (i.e. a total laryngectomy). Combined chemotherapy and
radiation therapy have played a major role in this clinical research
on larynx preservation with either induction chemotherapy before
irradiation or concurrent chemo-radiotherapy. Several random-
ized trials have been carried out and larynx preservation has been
validated as a reliable option. The accumulation of papers on this
topic over the past decades has led to consider sometimes that
surgery was disappearing from the therapeutic arsenal for mod-
erately and advanced larynx and hypopharynx cancers. If larynx
preservation is an undisputable advance in the management of
laryngopharyngeal malignancies, surgery should not be consid-
ered as an obsolete treatment and only indicated for salvage. This
situation may be explained by an overuse of the concept of “the
standard of care is...” that does not pay enough attention to the
potential gap between the selection of patients enrolled in clini-
cal trials and the daily practice. The purpose of this review is to
consider the current place of surgery in the armamentarium for
larynx and hypopharynx cancer in the era of larynx preservation.
HISTORICAL PERSPECTIVE
Surgery for larynx cancer was pioneered during the second half
of the 19th century. The first reported surgical procedures were
partial laryngeal resections. Actually the main milestone in lar-
ynx cancer surgery was the first total laryngectomy by Billroth in
1873. At the very beginning of the 20th century the first case of
larynx cancer treated by radiation therapy was reported in Paris.
For a long period of time surgery (either partial or radical) and
Over the past decades, randomized clinical trials have assessed and validated the concept of larynx preservation. This new
concept has obviously modified the treatment algorithm for laryngopharyngeal squamous cell carcinoma. However surgery
for larynx and hypopharynx cancer remains indicated in many cases. Initial partial surgery is indicated for early diseases.
This surgery may be performed endoscopically or openly. The results are excellent in terms of local control and function.
Transoral robotic surgery is under evaluation. Initial radical surgery is indicated for advanced diseases in case of very
infiltrative tumor, in case of cartilage destruction or when tolerance and/or compliance to chemotherapy-based approached
is questionable. Larynx preservation is to be discussed between these two situations. In randomized trials evaluating the
different larynx preservation strategies, a substantial number of larynxes could be preserved without compromising dis-
ease control or survival. The best approach in terms of quality of function preservation, overall acute and late toxicity,
disease control and survival is still a matter of clinical research. It must be stressed that salvage surgery is a definite part
of these larynx preservation protocols in order to maintain the ultimate disease control. This discussion underscored the
need of a multidisciplinary decision making and the need of a coordinated clinical research.
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ynx and hypopharynx cancers. In the 1970s, the German school
pioneered the endoscopic laser microsurgery. At the same time,
serial imaging (CTscan and MRI) provided tremendously precise
data on the local extension of the tumor allowing fine-tuning the
choice of surgical procedures adapted to each situation. Very re-
cently transoral robotic surgery appeared as a new tool for endo-
scopic surgery to be evaluated.
In the early 1980s chemotherapy, with the platinum compo-
unds, became an additional option and in particular opened the
era of larynx preservation clinical trials. Induction chemothera-
py (with the cisplatin-5 fluorouracil regimen) followed by radia-
tion therapy in case of a reduction of at least 50% of the primary
tumor size was the first experimental approach for larynx preser-
vation. From published randomized trials (1-5) carried out in the
US (VA trial) and in Europe (GETTEC trial and EORTC 24891
trial), it appeared that this approach did not compromise the ulti-
mate disease control and survival when compared with the con-
ventional treatment (total laryngectomy and postoperative radi-
ation therapy). The larynx could be preserved in around 60%
of the cases. A recent French trial (GORTEC 2000-01) compared
a more intensive induction chemotherapy regimen (adding doc-
etaxel to the conventional cisplatin-5 fluorouracil regimen). In
this trial the larynx preservation rate (around 70%) was signifi-
cantly higher with the triplet induction chemotherapy than with
the doublet one but without statistical difference in survival (6).
Concomitant chemo-radiotherapy (radiotherapy delivered ei-
ther concurrently or alternatively with chemotherapy) was there-
after compared to induction chemotherapy. One trial in the US
(RTOG 91-11) assessed concurrent chemo-radiotherapy (7, 8).
If concurrent chemo-radiotherapy provided significantly higher
larynx preservation (84%) than induction chemotherapy or radi-
ation therapy alone, overall survival, progression-free survival
and laryngectomy free survival did not significantly differ. One
European trial compared (9) alternating chemo-radiotherapy and
induction chemotherapy (EORTC 24954) but there was no sig-
nificant difference between both arms as regards survival and
larynx preservation.
More recently preliminary data suggested that induction che-
motherapy followed by concurrent chemo-radiotherapy (10),
radiotherapy with concurrent cetuximab (11) or induction che-
motherapy followed by radiotherapy and concurrent cetuximab
(12) should also be considered for larynx preservation.
Altered fractionation has also been reported as to provide bet-
ter results than conventional irradiation (13). But there is no ran-
domized trial specifically designed for assessing larynx preser-
vation.
There is no doubt that this clinical research has shifted some
paradigms in the treatment of larynx and hypopharynx cancer
leading to a declining use of surgery (14). However the discussion
about larynx preservation remains sometimes controversial. One
study evaluated the parallel evolution of care and of outcome
of larynx cancer in the US (15). In this study on 158,426 larynx
cancers, it appeared that from mid 80s to mid 90s the use of ch-
emo-radiotherapy increased and the use of surgery decreased
while survival progressively decreased over this period of time.
In this survey, survival seemed higher when patients had prima-
ry surgery. Another report (16) had a similar conclusion for stage
IV larynx cancer. Such data generated a discussion on the relia-
bility and justification of larynx preserving strategies (17). How-
ever it must be stressed that a similar survey conducted in the
European Union has found on the contrary a decrease in mortal-
ity due to larynx cancer between 1970 and 2003 (18) despite an
increasing popularity of larynx preservation protocols.
Most probably the discrepancies between the published trials
in terms of eligibility criteria, primary endpoints selection and
definition and secondary endpoints have generated some confu-
sion. In particular “larynx preservation” was assessed in some
studies only as “larynx in place” without capturing other data
such as tracheotomy or feeding tube. In other studies a very res-
trictive definition was used compiling “larynx in place, no resid-
ual tumor, no tracheotomy, no feeding tube.” In addition survival
was included in the primary endpoint (survival with a function-
al larynx in place) in few studies.
Two groups of experts have tried to clarify these issues in defin-
ing the guidelines for larynx cancer management (19) or for lar-
ynx preservation clinical trials (20, 21). Obviously the place of
surgery either as the initial treatment or as a salvage procedure
must be regularly clarified.
PARTIAL SURGERY FOR EARLY DISEASES
The head and neck surgeon has at his disposal an impressive num-
ber of partial procedures:
For the supraglottic area: endoscopic laser microsurgery, hy-
oepiglottectomy, supraglottic laryngectomy, laterally extend-
ed supraglottic laryngectomy and supracricoid partial laryn-
gectomy with cricohyoidopexy
For the glottic area: endoscopic laser microsurgery, cordec-
tomy, frontolateral laryngectomy, frontal anterior laryngec-
tomy, hemilaryngectomy and supracricoid partial laryngec-
tomy with cricohyoidoepiglottopexy
For the hypopharynx: endoscopic microsurgery, lateral par-
tial pharyngectomy, supracricoid hemilaryngopharyngec-
tomy, supracricoid hemilaryngopharyngectomy
In this list of surgical procedures the surgeon may select the
most appropriate one on the basis of the endoscopic and radio-
logic respective features. When properly selected and performed
this surgery insures the local control in more than 90% of the
cases (22). 
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with quite similar results. The choice between both options is ba-
sed on various parameters relating to the patient (age, occupa-
tion, compliance, whishes), to the tumor (size, macroscopic aspect,
history of precancerous changes).
Whatever the treatment the disease is controlled in the vast
majority of the cases, the most frequent carcinologic event during
the follow-up is the appearance of metachronous cancer. There
is no indication for adding chemotherapy to surgery or to radia-
tion therapy. These cases are not in the frame of larynx preser-
vation, the place of partial surgery is undisputable in this situation.
PARTIAL SURGERY FOR ADVANCED DISEASES
When surgery is selected for the initial treatment, most of patients
presenting with advanced larynx and hypopharynx carcinoma
are offered total laryngectomy. However either endoscopic or
open partial surgery may be still considered in selected cases.
Endoscopic laser microsurgery has been reported for rather
advanced tumors of the larynx (23-28) or of the hypopharynx
(29, 30). Most of the time an open surgery of the neck (for nodal
clearance) and a postoperative irradiation were associated to this
endoscopic microsurgery.
Supracricoid partial laryngectomy may be considered as the
largest partial surgical procedure. Most of the time this surgery
has been indicated for T2 diseases aiming to get better local con-
trol than with other partial procedures. However there are some
reports of such a surgery performed for more advanced cases
(31-34).
It is undisputable that these indications are quite rare and only
available for much selected patients and tumors and for highly
experienced teams, but they do exist.
SURGERY AND ORGAN PRESERVATION
The concept of larynx preservation has probably too often been
misinterpreted or insufficiently clarified.
First there is a semantic point that must be repeated each time
organ preservation is discussed. Organ preservation means and
only means that the entire organ is still in place whether it is still
functioning or not. Keeping in place an organ that does not func-
tion any longer is of very limited interest for the patients. To this
extend acute or late toxicity of non-surgical treatments may com-
promise the function of the preserved organ. What is meaning-
ful actually is to preserve the function whether the organ is entire-
ly preserved or not. That why partial surgery as an alternative
to a total laryngectomy when feasible is also a larynx preserva-
tion strategy. To be honest it must be recognized that postoper-
ative complications may also occur and compromise the function
(as said above, selection of patient and expertise are prerequi-
sites). It must be underscored that this distinction between larynx
preservation and larynx function preservation is not always made
even in published randomized trials. This distinction is also to be
taken into account in the current ambience of treatment intensi-
fication that may generate substantial toxicity compromising de-
finitively the larynx function.
Larynx function preservation is not the only goal when treat-
ing an advanced larynx or hypopharynx cancer. What patients
are expecting first is to be cured and to survive long (35, 36). This
means that we have to propose an alternative to a total laryngec-
tomy pending this alternative may provide disease control and
survival at least as good as initial radical surgery does. This means
that the best way to assess a larynx preservation trial is to select
a primary endpoint mixing the organ and function preservation,
the local control and survival. It must be underscored that to date
if survival was not compromised in the larynx preservation tri-
als, none of the non surgical approaches has provided a better
survival than initial radical surgery. In addition in trials compar-
ing different approaches the difference in terms of larynx preser-
vation did not translate into any difference in terms of overall
disease-free and laryngectomy-free survival. This must be hon-
estly and clearly explained to the patient before deciding a lar-
ynx preservation protocol as all patients are no willing to trade
off chances of cure for keeping their larynx in place.
Larynx preservation is often described as a “non surgical treat-
ment”. This presentation is not accurate: larynx preservation is
a priori a non-surgical approach that may turn into a surgical in-
dication at any time if necessary. Actually both survival and ulti-
mate disease control have been maintained in the larynx preser-
vation trials thanks to adequate salvage surgery. Salvage surgery
may be indicated: 1) after induction chemotherapy in patients
who do not respond enough at the primary site, 2) after irradia-
tion delivered after induction chemotherapy in case of residual
local disease, 3) after concurrent chemo-radiotherapy in case of
residual local disease or 4) during the follow-up in case of relapse.
Before the clinical research on larynx preservation was initiated,
salvage surgery for irradiation failure had known major improve-
ment in terms of postoperative morbidity and mortality thanks
to the use of reliable flaps (in particular the major pectoralis mus-
cular or myo-cutaneous flaps) for covering pharyngeal sutures
and for protecting vessels. From the experience with induction
chemotherapy we have learned that performing salvage surgery
after induction chemotherapy was not a concern either for the
quality of surgical margins or as regards postoperative morbidi-
ty (2). Late salvage surgery after irradiation appeared also fea-
sible with acceptable postoperative courses. There are fewer data
on salvage surgery after concurrent chemo-radiotherapy for lar-
ynx preservation. In the RTOG-11 study the postoperative mor-
bidity after salvage surgery was acceptable (37). However in the
daily practice head and neck surgeons often face some concerns.
During the phase of acute toxicity (epidermitis, mucositis, edema
etc.) the difficulties come from the ability of detecting and assess-
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or in the neck. Salvage surgery may be compromised due to the
uncertainties in evaluating surgical margins even with the use of
frozen sections and due to potential healing problems as well.
During the phase of late toxicity (fibrosis, sclerosis, edema etc.)
the difficulties come also in detection and evaluation of a recur-
rent disease. Surgery may be compromised by the difficulties of
dissecting fibrotic tissues, by an increase rate of postoperative
complications (early complications for healing or late complica-
tions such as stenosis and stricture). The risk of increased rates
of acute and late toxicity must be thoroughly considered when
discussing treatment intensification as in addition to compromis-
ing tolerance and compliance to treatment it could also compro-
mise salvage surgery. There are also unanswered questions about
salvage surgery. One is the type of salvage resection of the pri-
mary tumor. May partial surgery be an option? There are emerg-
ing data reporting partial salvage surgery of the larynx. But there
is about no data of partial surgery for larynx preservation failure.
In the absence of robust argument for or against partial surgery,
we must be pragmatic. In case of persistent disease after chemot-
herapy, radiotherapy, concurrent chemo-radiotherapy or con-
current bio-chemotherapy in patients for whom the initial surgi-
cal indication would have been a total laryngectomy, radical sal-
vage surgery is the logical proposal. For recurrent diseases dur-
ing the follow-up, most of the time radical salvage surgery is the
best option, however in case of late recurrence partial salvage
surgery may be proposed in selected cases according to the local
extension, the absence of severe tissue sequel and according to
the length of the free interval. The other issue is the discussion
of a systematic neck dissection in case of initial extensive nodal
context. This attitude has been often advocated in the US and is
certainly a “security option” but the risk of increasing late toxi-
city has been reported (38).
CONCLUSION
Larynx function preservation is one of the major advances
that have been achieved over the past decades. However the
indications of larynx preservation, whatever the protocol (based
on the selection of patients with induction chemotherapy or based
on concurrent chemo-radiotherapy) are limited to precise clini-
cal situations. When partial surgery is feasible the surgical indi-
cation must be maintained. In case of very infiltrative transglot-
tic tumors or in case of tumors extending through the cartilage,
upfront radical surgery must be indicated. Larynx preservation
is indicated between these two clinical situations when tolerance
and compliance to treatment seem acceptable. However the pa-
tients enrolled in larynx preservation protocols must be informed
that surgery could be indicated during the process of these pro-
tocols. Finally it must be underscored that as there are different
treatment options, the best way to select the most appropriate
one is a multidisciplinary decision making that is the golden stan-
dard of care.
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